ECE2024 Eposter Presentations Calcium and Bone (102 abstracts)
1National Medical Institute of the Ministry of the Interior and Administration, Department of Internal Medicine, Endocrinology and Diabetology, Warsaw, Poland; 2National Medical Institute of the Ministry of the Interior and Administration, Students Scientific Group of the Medical University of Warsaw at the Department of Internal Medicine, Endocrinology and Diabetology, Warsaw, Poland; 3Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland, Department of Human Epigenetics, Warsaw, Poland
Background : EhlersDanlos syndrome encompasses a group of genetic conditions characterized by alterations in connective tissue structure, with the consequent increased risk of developing osteopenia, osteoporosis, and incurring fractures. Maintaining vitamin D levels within normal limits is known to play an important role in preventing these complications, which seems to be particularly important in patients with EhlersDanlos syndrome. The purpose of this study was to assess serum 25-hydroxyvitamin D, or 25(OH)D, levels in women with EhlersDanlos syndrome.
Material and methods: The study involved a prospective assessment of 30 female patients, aged 2053 years, with hypermobile or classical EhlersDanlos syndrome. All patients underwent calcium and phosphorus metabolism testing and bone mineral density (BMD) scans of the femoral neck and lumbar spine. The patients were divided into two groups: those with vitamin D deficiency, defined as serum 25(OH)D levels of < 30 ng/ml (group 1, n=18) and those with normal (> 30 ng/ml) 25(OH)D levels (group 2, n=12).
Results: Eighteen patients (60%) showed vitamin 25(OH)D deficiency, with three of those (16.7%) showing secondary hyperparathyroidism. Study groups 1 and 2 showed no significant differences in terms of serum levels of calcium (2.4±0.09 mmol/l vs 2.39±0.07 mmol/l, P=0.88), phosphorus (3.51±0.7 mg/dl vs 3.42±0.51 mg/dl, P=0.86), bone-specific alkaline phosphatase (10.36±3.06 µg/l vs 8.28±1.31 µg/l, P=0.007), beta-CrossLaps (0.39±0.19 ng/ml vs 0.39±0.17 ng/ml, P=0.69), or osteocalcin (20.14±8 ng/ml vs 21.23±6.67 ng/ml, P=0.46), femoral neck BMD (0.95±0.12 g/cm2 vs 0.92±0.13 g/cm2, P=0.57), or lumbar spine BMD (0.12±0.16 g/cm2 vs 0.13±0.11 g/cm2, P=0.14).
Conclusions: Sixty percent of patients with EhlersDanlos syndrome showed vitamin 25(OH)D deficiency. Parameters of calciumphosphorus metabolism in these patients were not significantly different from those in patients with normal serum vitamin 25(OH)D levels.